Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted strong year-over-year sales growth for 2025, driven partially by expected EU approval and initial launch in Germany later this year.
Key Takeaways
- Madrigal continues to beat Wall Street projections for the launch of Rezdiffra, the first approved MASH drug.
The Conshohocken, PA-based company also reported two-year data from a cohort of MASH patients with cirrhosis from an ongoing study,...